ALK and inflammatory myofibroblastic tumor: In over 50% of IMT patients, ALK overexpression is detected by immunohistochemistry, and ALK-related translocations are also detected; there are variations of partner fusion genes, i.e., TPM3, TPM4, CLTC, RANBP2, and ATIC [7].